Sortiert nach Autor

Publikationen - sortiert nach Autor

• Rommer P, Puchhammer‐Stöckl E, Lassmann H, Berger T, Vietzen H (2024) Ineffective control of Epstein–Barr virus infection is seen in MS: What is next? Clin Transl Med, 14 (2): :e1596

• Krajnc N, Schmidbauer V, Leinkauf J, Haider L, Bsteh G, Kasprian G, Leutmezer F, Kornek B, Rommer P, Berger T, Lassmann H, Dal-Bianco A, Hametner S (2023) Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis Mult Scler, 29(11-12): 1406-1417
• Zakani M, Nigritinou M, Ponleitner M, Takai Y, Hofmann D, Hillebrand S, Höftberger R, Bauer J, Lasztoczi B, Misu T, Kasprian G, Rommer P, Bradl M (2023) Paths to hippocampal damage in neuromyelitis optica spectrum disorders Neuropathol Appl Neurobiol, 49 (2)
  | Article (PDF) || Weblink |
• Krajnc N, Dal-Bianco A, Leutmezer F, Kasprian G, Pemp B, Kornek B, Berger T, Rommer P, Hametner S, Lassmann H, Bsteh G (2023) Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis Mult Scler, 29(3): 374-384

• Krajnc N, Bsteh G, Kasprian G, Zrzavy T, Kornek B, Berger T, Leutmezer F, Rommer P, Lassmann H, Hametner S, Dal-Bianco A (2022) Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis Front Neurol, 13: 928582

• Altmann P, Leithner K, Leutmezer F, Monschein T, Ponleitner M, Stattmann M, Rommer P, Zrzavy T, Zulehner G, Berek K, Berger T, Bsteh G (2021) Sexuality and Multiple Sclerosis: Patient and Doctor Perspectives JSM, 18 (4): 743-749
• Altmann P, Leutmezer F, Leithner K, Monschein T, Ponleitner M, Stattmann M, Rommer P, Zrzavy T, Zulehner G, Berek K, Berger T, Bsteh G (2021) Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis Front Neurol, 12: 618370
• Wurm R, Arfsten H, Muqaku B, Ponleitner M, Bileck A, Altmann P, Rommer P, Seidel S, Hubner P, Sterz F, Heinz G, Gerner C, Adlbrecht C, Distelmaier K (2021) Prediction of Neurological Recovery After Cardiac Arrest Using Neurofilament Light Chain is Improved by a Proteomics-Based Multimarker Panel Neurocrit Care,
• Dal-Bianco A, Schranzer R, Grabner G, Lanzinger M, Kolbrink S, Pusswald G, Altmann P, Ponleitner M, Weber M, Kornek B, Zebenholzer K, Schmied C, Berger T, Lassmann H, Trattnig S, Hametner S, Leutmezer F, Rommer P (2021) Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study Front Neurol, 12: 632749
• Zrzavy T, Wielandner A, Haider L, Bartsch S, Leutmezer F, Berger T, Nenning KH, Rauscher A, Rommer P, Kasprian G (2021) FLAIR2 post-processing: improving MS lesion detection in standard MS imaging protocols J Neurol,
• Bsteh G, Hegen H, Altmann P, Auer M, Berek K, Di Pauli F, Leutmezer F, Rommer P, Wurth S, Zinganell A, Zrzavy T, Deisenhammer F, Berger T (2021) Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis Eur J Neurol, 28 (6): 2037-2045
• Zrzavy T, Daniels E, Stuka N, Weber D, Winkelmann A, Rauschka H, Hecker M, Aboulenein-Djamshidian F, Meister S, Leutmezer F, Berger T, Bsteh G, Zettl UK, Rommer P (2021) Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis Therapeutic Advances in Chronic Disease, 12: 204062232110243
• Ricken G, Zrzavy T, Macher S, Altmann P, Troger J, Falk K, Kiefer A, Fichtenbaum A, Mitulovic G, Kubista H, Wandinger K, Rommer P, Bartsch T, Berger T, Weber J, Leypoldt F, Höftberger R (2021) Autoimmune Global Amnesia as Manifestation of AMPAR Encephalitis and Neuropathologic Findings Neurol Neuroimmunol Neuroinfl, 8 (4): e1019
• Milenkovic I, Sycha T, Berger-Sieczkowski E, Rommer P, Czerny C, Wiest G (2021) Pulse-synchronous torsional nystagmus PN, 21 (5): 445-447
• Macher S, Milenkovic I, Zrzavy T, Höftberger R, Seidel S, Berger-Sieczkowski E, Berger T, Rommer P, Wiest G (2021) Ocular Motor Abnormalities in Anti-IgLON5 Disease Front Immunol, 12
• Steinmaurer A, Wimmer I, Berger T, Rommer P, Sellner J (2021) Bruton's tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis Curr Pharm Des, 27
• Zrzavy T, Höftberger R, Wimmer I, Berger T, Rommer P, Macher S (2021) Longitudinal CSF Findings in Autoimmune Encephalitis—A Monocentric Cohort Study Front Immunol, 12
• Zrzavy T, Endmayr V, Bauer J, Macher S, Mossaheb N, Schwaiger C, Ricken G, Winklehner M, Glatter S, Breu M, Wimmer I, Kovacs G, Risser D, Klupp N, Simonitsch‐Klupp I, Roetzer T, Rommer P, Berger T, Gelpi E, Lassmann H, Graus F, Dalmau J, Höftberger R (2021) Neuropathological variability within a spectrum of NMDAR‐encephalitis. Ann Neurol, : 2021 Sep 25. doi: 10.1002/ana.26223. Online ahead of print.
• Weinhofer I, Rommer P, Zierfuss B, Altmann P, Foiani M, Heslegrave A, Zetterberg H, Gleiss A, Musolino P, Gong Y, Forss-Petter S, Berger T, Eichler F, Aubourg P, Köhler W, Berger J (2021) Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy Nat Commun, 12 (1): 1816
• Dal-Bianco A, Grabner G, Kronnerwetter C, Weber M, Kornek B, Kasprian G, Berger T, Leutmezer F, Rommer P, Trattnig S, Lassmann H, Hametner S (2021) Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI Brain, 144(3): 833-847

• Monschein T, Salhofer-Polanyi S, Altmann P, Zrzavy T, Dal-Bianco A, Bsteh G, Rommer P, Berger T, Leutmezer F (2020) Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis J Neurol, 268 (4): 1247-1253
• Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hümmert M, Ringelstein M, Rommer P, Ayzenberg I, Ruprecht K, Klotz L, Asgari N, Zrzavy T, Höftberger R, Tobia R, Buttmann M, Fechner K, Schanda K, Weber M, Asseyer S, Haas J, Lechner C, Kleiter I, Aktas O, Trebst C, Rostasy K, Reindl M, Kümpfel T, Paul F, Wildemann B, (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients J Neuroinflammation, 17 (1)
• Altmann P, De Simoni D, Kaider A, Ludwig B, Rath J, Leutmezer F, Zimprich F, Hoeftberger R, Lunn M, Heslegrave A, Berger T, Zetterberg H, Rommer P (2020) Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome J Neuroinflammation, 17 (1)
• Macher S, Zrzavy T, Höftberger R, Altmann P, Pataraia E, Zimprich F, Berger T, Rommer P (2020) Longitudinal measurement of cerebrospinal fluid neurofilament light in anti‐N‐methyl‐D‐aspartate receptor encephalitis Eur J Neurol, 28 (4): 1401-1405
• Zrzavy T, Wimmer I, Rommer P, Berger T (2020) Immunology of COVID‐19 and disease‐modifying therapies: the good, the bad and the unknown Eur J Neurol,
• Tsymala I, Nigritinou M, Zeka B, Schulz R, Niederschick F, Matković M, Bauer I, Szalay M, Schanda K, Lerch M, Misu T, Fujihara K, Bennett J, Dahle C, Pache F, Rommer P, Leutmezer F, Illes Z, Leite M, Palace J, Scholze P, Reindl M, Lassmann H, Bradl M (2020) Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes Acta Neuropathologica Communications, 15; 8 (1)
  | Supplement |

• Heckova E, Strasser B, Hangel G, Považan M, Dal-Bianco A, Rommer P, Bednarik P, Gruber S, Leutmezer F, Lassmann H, Trattnig S, Bogner W (2019) 7 T Magnetic Resonance Spectroscopic Imaging in Multiple Sclerosis Invest Radiol, 54(4): 247-254

• Zrzavy T, Kollaritsch H, Rommer P, Boxberger N, Loebermann M, Wimmer I, Winkelmann A, Zettl U (2019) Vaccination in Multiple Sclerosis: Friend or Foe? Front Immunol, 10

• Ricken G, Schwaiger C, De Simoni D, Pichler V, Lang J, Glatter S, Macher S, Rommer P, Scholze P, Kubista H, Koneczny I, Höftberger R (2018) Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis Front Neurol, 9: 841

• Rommer P, Zschocke J, Fowler B, Födinger M, Konstantopoulou V, Möslinger D, Stögmann E, Suess E, Baumgartner M, Auff E, Sunder-Plassmann G (2017) Manifestations of neurological symptoms and thromboembolism in adults with MTHFR-deficiency J Neurol Sci, 383: 123-127
• Salhofer-Polanyi S, Cetin H, Leutmezer F, Baumgartner A, Blechinger S, Dal-Bianco A, Altmann P, Bajer-Kornek B, Rommer P, Guger M, Leitner-Bohn D, Reichardt B, Alasti F, Temsch W, Stamm T (2017) Epidemiology of Multiple Sclerosis in Austria Neuroepidemiol, 49 (1-2): 40-44
• Ehler J, Blechinger S, Rommer P, Koball S, Mitzner S, Hartung H, Leutmezer F, Sauer M, Zettl U (2017) Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients—A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness Int J Mol Sci, 18 (8): 1749
• Platho-Elwischger K, Kranz G, Sycha T, Dunkler D, Rommer P, Mueller C, Auff E, Wiest G (2017) Plasticity of static graviceptive function in patients with cervical dystonia J Neurol Sci, 373: 230-235
• Körtvélyessy P, Breu M, Pawlitzki M, Metz I, Heinze H, Matzke M, Mawrin C, Rommer P, Kovacs G, Mitter C, Reindl M, Brück W, Wandinger K, Lassmann H, Höftberger R, Leypoldt F (2017) ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports Neurol Neuroimmunol Neuroinfl, 4 (3): e335

• Rommer P, Sühnel A, König N, Zettl U (2016) Coping with multiple sclerosis-the role of social support Acta Neurol Scand, 136 (1): 11-16
• Skierlo S, Rommer P, Zettl U (2016) Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry Acta Neurol Scand, 135 (4): 394-399
• Zeka B, Hastermann M, Kaufmann N, Schanda K, Pende M, Misu T, Rommer P, Fujihara K, Nakashima I, Dahle C, Leutmezer F, Reindl M, Lassmann H, Bradl M (2016) Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD Acta Neuropathologica Communications, 4 (1): 82

• Zeka B, Hastermann M, Hochmeister S, Kögl N, Kaufmann N, Schanda K, Mader S, Misu T, Rommer P, Fujihara K, Illes Z, Leutmezer F, Sato D, Nakashima I, Reindl M, Lassmann H, Bradl M (2015) Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS Acta Neuropathol, 130 (6): 783-798
• Rommer P, Kamin F, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl U (2015) Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients CNS Neurosci Ther, 22 (1): 74-79
• Rommer P, Fuchs D, Leblhuber F, Schroth R, Greilberger M, Tafeit E, Greilberger J (2015) Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease Neurodeg Dis, 16 (3-4): 284-289
• Rommer P, , Dörner T, Freivogel K, Haas J, Kieseier B, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl U (2015) Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID) J Neuroimmune Pharmacol, 11 (1): 1-8
• Rommer P, Beisteiner R, Elwischger K, Auff E, Wiest G (2015) Neuromagnetic Cortical Activation during Initiation of Optokinetic Nystagmus: An MEG Pilot Study Audiol. Neurootol., 20 (3): 189-194
• Rommer P, Buckow K, Ellenberger D, Friede T, Pitschnau-Michel D, Fuge J, Stüve O, Zettl U, (2015) Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis - an observational study Eur. J. Clin. Invest., 45 (6): 587-593
• Rommer P, Wiest G, Kronnerwetter C, Zach H, Loader B, Elwischger K, Trattnig S (2015) 7-Tesla MRI demonstrates absence of structural lesions in patients with vestibular paroxysmia Front Neuroanat, 9

• Zettl U, Rommer P, Hipp P, Patejdl R (2015) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis Ther Adv Neurol Disord, 9 (1): 9-30

• Ringelstein M, Aktas O, Harmel J, Prayer D, Jarius S, Wildemann B, Hartung H, Salhofer-Polanyi S, Leutmezer F, Rommer P (2014) Biopsie bei tumorverdächtiger spinaler Raumforderung: Fallstrick Neuromyelitis optica Nervenarzt, 85 (10): 1298-1303
• Rommer P, Kamin F, Petzold A, Tumani H, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl U (2014) Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients Mol Diagn Ther, 18 (6): 631-637
• Rommer P, Greilberger J, Salhofer-Polanyi S, Auff E, Leutmezer F, Herwig R (2014) Elevated Levels of Carbonyl Proteins in Cerebrospinal Fluid of Patients with Neurodegenerative Diseases Tohoku J. Exp. Med., 234 (4): 313-317
• Wittstock M, Rommer P, Schiffmann F, Jügelt K, Stüwe S, Benecke R, Schiffmann D, Zettl U (2014) Effect of Methylprednisolone on Mammalian Neuronal Networks In Vitro Cell. Mol. Neurobiol., 35 (1): 111-114
• Kamin F, Rommer P, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl U (2014) Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity Spinal Cord, 53 (2): 109-113
• Dudesek A, Rimmele F, Tesar S, Kolbaske S, Rommer P, Benecke R, Zettl U (2014) CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders Clin. Exp. Immunol., 175 (3): 385-396

• Rommer P, Dudesek A, Stüve O, Zettl U (2014) Monoclonal antibodies in treatment of multiple sclerosis Clin. Exp. Immunol., 175 (3): 373-384
• Rommer P, Zettl U, Kieseier B, Hartung H, Menge T, Frohman E, Greenberg B, Hemmer B, Stüve O (2014) Requirement for safety monitoring for approved multiple sclerosis therapies: an overview Clin. Exp. Immunol., 175 (3): 397-407

• Gaggl M, Kain R, Jaksch P, Haider D, Mundigler G, Voigtländer T, Sunder-Plassmann R, Rommer P, Klepetko W, Sunder-Plassmann G (2013) A Single Lung Transplant in a Patient with Fabry Disease: Causality or Far-Fetched? A Case Report Case Rep Transplant, 2013: 905743
• Aboul-Enein F, Seifert-Held T, Mader S, Kuenz B, Lutterotti A, Rauschka H, Rommer P, Leutmezer F, Vass K, Flamm-Horak A, Stepansky R, Lang W, Fertl E, Schlager T, Heller T, Eggers C, Safoschnik G, Fuchs S, Kraus J, Assar H, Guggenberger S, Reisz M, Schnabl P, Komposch M, Simschitz P, Skrobal A, Moser A, Jeschow M, Stadlbauer D, Freimüller M, Guger M, Schmidegg S, Franta C, Weiser V, Koppi S, Niederkorn-Duft M, Raber B, Schmeissner I, Jecel J, Tinchon A, Storch M, Reindl M, Berger T, Kristoferitsch W (2013) Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People PLoS One, 8 (11): e79649

• Rommer P, Stüve O (2013) Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment—Past, Present, and Future Aspects Curr Treat Options Neurol, 15 (3): 241-258

• Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer P, Ruprecht K, Ringelstein M, Aktas O, Kristoferitsch W, Wildemann B (2012) Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry J Neurol Sci, 320 (1-2): 32-37

• Elwischger K, Rommer P, Prayer D, Mueller C, Auff E, Wiest G (2011) Thalamic astasia from isolated centromedian thalamic infarction Neurology, 78 (2): 146-147